WASHINGTON--(BUSINESS WIRE)--EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity and other gastrointestinal disorders, announced that interim clinical results for the company’s VBLOC™ vagal blocking therapy device, the Maestro™ RF2 System, were presented today at the 25th annual meeting of the American Society for Metabolic and Bariatric Surgery, being held June 15–20 in Washington, D.C.
